News

Peptide 101: A Deep Dive into Peptide Drug Market, Development Timeline, and Strategies in Delivery

Views: 68     Author: Unibest Industrial     Publish Time: 2024-01-18      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

While everything from dietary changes to high-cost surgeries has been explored to combat diseases, therapeutics derived from peptides have risen as a powerful strategy. Over the past few years, peptide drugs have swept through the pharmaceutical market, redefining treatment approaches for various disorders. This article aims to demystify the booming peptide drug market, delve into its steady growth timeline, and spotlight the sophisticated delivery strategies shaping its success.


The Booming Peptide Drug Market

Pharmaceutical dynamics have been considerably altered with the advent of peptide drugs. As per Grand View Research, the valuation of the global peptide therapeutics market impressively reached US $39.3 billion in 2021. With an encouraging compound annual growth rate of 6.4%, the market is predicted to catapult to a remarkable US $68.7 billion by 2030.


This surge in market value has been propelled by advances in nucleic acid and protein-based approaches, paving the way for peptide drug discovery. For instance, metabolic disorders such as diabetes accounted for a significant ∼37.1% of the peptide therapeutics market share in 2021. Both insulin and non-insulin-based peptides are now listed among the top 200 pharmaceuticals, weaving a success story echoed across big pharma names like Eli Lilly, Pfizer, Amgen, and Takeda, to name a few.



The Growth Trajectory of Peptide Drug Approvals

Reflecting on the FDA-approved drugs (from 1940 until July 2022), peptides constitute 6%, small molecules signify 83%, whereas biologics represent 11%. But don't let the numbers fool you - the demand for peptide therapeutics has catapulted dynamically, leading to more than a century of peptide drug approvals.


fda approved peptide drugs

Status of peptide drugs approved by US FDA from 1940 to July 2022. Src: Sharma, K., Sharma, K. K., Sharma, A. & Jain, R. Peptide-based drug discovery: Current status and recent advances. Drug Discovery Today 28, 103464 (2023).


This journey began around the 1940s, taking its baby steps until the 1960s. The era marked the dawn of peptide antibiotics, propelling significant strides toward future advancements. However, it was in the 1980s when the treatment of diabetes witnessed a revolution, owing to the approval of the coveted antidiabetic drug, recombinant insulin.


Peptide drug timeline

Peptide drug development timeline. Src: Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat Rev Drug Discov 20, 309–325 (2021).


From then on, peptide therapeutics began expanding its reach, sprouting into the anticancer, cardiovascular, and cardioprotective sections. The growth was in full swing by the 2000s, embracing exciting peptide drug developments, with the most recent decade seeing the highest number of approvals.


Innovative Peptide Drug Delivery Mechanisms

For peptide drugs to function effectively, overthrowing renal clearance that could clear off the unmodified peptides rapidly is critical. In finding mechanisms for increasing their molecular weight, the scientific community has found hope in lipidation, conjugation to larger proteins, and pegylation. These strategies collectively thwart the risks of proteolytic degradation through steric hindrance.


Take, for instance, Semaglutide. Integral in treating type 2 diabetes and obesity, the drug's delivery strategy uses lipid conjugation. The linked fatty acid is a C18 fatty acid, Octadecadioic acid. This Semaglutide side chain binds to serum albumin, reducing the degradation and elimination significantly. This not only delays release from the injection site but also curbs immunogenic responses. In addition, when Semaglutide is co-formulated with an absorption promotor or permeation enhancer, such as SNAC, the bioavailability increases further. This makes it possible to administer the drug orally.


Other groundbreaking strategies include pegylation and selective conjugation to serum albumin or immunoglobulin. These maneuvers have expedited the duration of action, expanding the horizons of what peptide drugs could achieve.

In Conclusion

The pharmaceutical landscape beholds an exciting future, echoing the rise of peptide drugs. Shaped by advances in the market, a steady development timeline, and sophisticated delivery strategies, therapies like Semaglutide are truly revolutionizing healthcare. The world anticipates what the next chapter of this journey unfolds. The fervor propels Unibest in its continuous strides towards peptide-based drug discovery, opening avenues to a healthier world. Stay with us for more updates in this thrilling sector.



References


1. Sharma, K., Sharma, K. K., Sharma, A. & Jain, R. Peptide-based drug discovery: Current status and recent advances. Drug Discovery Today 28, 103464 (2023).
 
2. Muttenthaler, M., King, G. F., Adams, D. J. & Alewood, P. F. Trends in peptide drug discovery. Nat Rev Drug Discov 20, 309–325 (2021).